Annals of hepatology最新文献

{"title":"Advancing stem cell therapy in liver failure: Critical insights from meta-analysis","authors":"Jinyu Wu , Yun Liao","doi":"10.1016/j.aohep.2025.101911","DOIUrl":"10.1016/j.aohep.2025.101911","url":null,"abstract":"","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"30 1","pages":"Article 101911"},"PeriodicalIF":3.7,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143741870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on \"MAFLD criteria are better than MASLD criteria at predicting the risk of chronic kidney disease\".","authors":"Ying Ma, Na Lv, Fang Bai","doi":"10.1016/j.aohep.2025.101909","DOIUrl":"10.1016/j.aohep.2025.101909","url":null,"abstract":"","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":" ","pages":"101909"},"PeriodicalIF":3.7,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143741827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Future directions of stem cell therapy for liver failure: Insights from a meta-analysis.","authors":"Shenglong Lin, Haibing Gao, Yueyong Zhu","doi":"10.1016/j.aohep.2025.101912","DOIUrl":"10.1016/j.aohep.2025.101912","url":null,"abstract":"","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":" ","pages":"101912"},"PeriodicalIF":3.7,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143741879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Body mass index and diabetes predict severity of liver fibrosis across the spectrum of steatotic liver disease.","authors":"Eda Kaya, Eduardo Vilar-Gomez, Raj Vuppalanchi, Yusuf Yilmaz","doi":"10.1016/j.aohep.2025.101907","DOIUrl":"10.1016/j.aohep.2025.101907","url":null,"abstract":"<p><strong>Introduction and objectives: </strong>Recent evidence indicates that metabolic dysfunction and alcohol-associated steatotic liver disease (MetALD), a newly defined subgroup of steatotic liver disease (SLD), may have a worse prognosis than metabolic dysfunction-associated steatotic liver disease (MASLD). This study examines the clinical factors influencing the severity of MetALD to inform and improve future management strategies.</p><p><strong>Patients and methods: </strong>Data from the 2017-2020 National Health and Nutrition Examination Surveys (NHANES), involving 7745 adults with valid elastography measurements, were utilized to define and estimate the prevalence of MASLD, MetALD, and alcohol liver disease (ALD). Controlled attenuation parameter (CAP) ≥285 dB/m, liver stiffness measurement (LSM) ≥8 kPa, and ≥12 kPa indicated the presence of hepatic steatosis, clinically significant fibrosis, and advanced fibrosis, respectively.</p><p><strong>Results: </strong>The prevalence of MetALD was 4 % (N=287), compared to 24 % (N=2049) for MASLD and 7 % (N=486) for ALD. The prevalence of significant fibrosis and advanced fibrosis in MetALD was 10.8 % and 3.1 %, respectively, compared to 24.7 % and 9.8 % in MASLD, and 15 % and 8 % in ALD. Logistic regression analysis among MetALD patients showed that higher body mass index (BMI) (odds ratio [OR]: 1.15, 95 % CI: 1.08-1.23, P<0.01) and diabetes mellitus (DM) (OR: 3.0, 95 % CI: 1.06-6.2, P<0.01) were associated with an increased risk of fibrosis. These factors were also identified as independent risk factors for fibrosis in patients with MASLD and ALD.</p><p><strong>Conclusions: </strong>MetALD had the lowest prevalence and fibrosis severity among the three groups of SLD. Elevated BMI and DM were associated with the severity of liver disease, and these findings provide a rationale for the use of obesity- and diabetes-targeted medications in these individuals.</p>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":" ","pages":"101907"},"PeriodicalIF":3.7,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143741820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Burden of disease and risk factors for primary liver cancer by etiology in the United States, 1990-2021: Results from the Global Burden of Disease study, 2021.","authors":"Duanyu Wang, Minghao Tan, Socheat Touch, Samnang Kouy, Syphanna Sou, Kun Liu, Youwen Zhu, Hong Zhu, Pengkhun Nov","doi":"10.1016/j.aohep.2025.101906","DOIUrl":"10.1016/j.aohep.2025.101906","url":null,"abstract":"<p><strong>Introduction and objectives: </strong>The distribution of major causes of liver cancer (LC) in the United States (US) has changed significantly over time. This study analyzes recent temporal trends in the causes of LC in the US from 1990 to 2021 and predicts future trends.</p><p><strong>Materials and methods: </strong>We obtained detailed data on LC in the US from the Global Burden of Disease (GBD) 2021 study. Estimated annual percentage change (EAPC) values for LC in the US were then calculated using linear regression models. An exponential smoothing (ES) projection model and Bayesian Age-Period-Cohort (BAPC) projection model were then used to predict the future disease burden of LC. Risk factors for LC were also assessed.</p><p><strong>Results: </strong>In 2021, the disease burden of LC in the US was significantly higher than in 1990. Hepatitis C virus (HCV)-associated LC resulted in the greatest burden of disease. The fastest growing burden of disease was attributed to metabolic dysfunction-associated steatotic liver disease (MASLD)-associated LC. Higher burdens of disease were seen in older and male populations.</p><p><strong>Conclusions: </strong>In the US, the disease burden of LC from different etiologies continues to rise. As such, targeted prevention and control strategies should be developed to address these unique disease characteristics.</p>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":" ","pages":"101906"},"PeriodicalIF":3.7,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143690351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Latin American expert opinion letter on the feasibility of systemic therapies in combination with locoregional therapies for hepatocellular carcinoma.","authors":"Margarita Anders, Angelo Z Mattos, José D Debes, Oscar Beltran, Pablo Coste, Juan Ignacio Marín, Aline Lopes Chagas, Josemaría Menéndez, Enrique Carrera Estupiñan, Javier Diaz Ferrer, Angelo A Mattos, Federico Piñero","doi":"10.1016/j.aohep.2025.101905","DOIUrl":"10.1016/j.aohep.2025.101905","url":null,"abstract":"<p><p>Recent advances in the systemic treatment of advanced hepatocellular carcinoma (HCC) with immunotherapy have once again reignited discussion over the role of combined therapy in earlier stages. This year, different international meetings have presented recent results from clinical trials on adjuvant therapy alone (IMBrave-050) and combined with transarterial chemoembolization (EMERALD-1 and LEAP-12). Increased enthusiasm for the use of adjuvant and neoadjuvant therapy for liver transplantation, surgery, and local-regional treatment of HCC has been shown. However, the initial results from these trials should be interpreted cautiously as we wait for final analyses and effects on overall survival. In this position paper from the special interest group from the Latin American Association for the Study of Liver Diseases (ALEH), we underline the caveats of the applicability of these potential treatments in our region, explore points of agreement, and highlight areas of uncertainty. Moreover, we underscore the role of hepatologists in the clinical decision-making process and management of these patients.</p>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":" ","pages":"101905"},"PeriodicalIF":3.7,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143690353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Naringenin attenuates early hepatocarcinogenesis induced by a MASH model.","authors":"Linda Vanessa Márquez-Quiroga, Aline Barboza-López, Jose Y Suárez-Castillo, Irina Cardoso-Lezama, Miguel Á Fuentes-Figueroa, Eduardo E Vargas-Pozada, Juan D Rodriguez-Callejas, Erika Ramos-Tovar, Carolina Piña-Vázquez, Jaime Arellanes-Robledo, Saúl Villa-Treviño, Pablo Muriel","doi":"10.1016/j.aohep.2025.101897","DOIUrl":"10.1016/j.aohep.2025.101897","url":null,"abstract":"<p><strong>Introduction and objectives: </strong>Nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome plays a critical role in the progression of metabolic dysfunction-associated steatohepatitis (MASH). Here, we investigated the effects of naringenin (NAR) on early hepatocellular carcinoma (HCC) experimentally induced in a rat MASH model and whether the NLRP3 inflammasome/pyroptosis pathway was involved.</p><p><strong>Materials and methods: </strong>The animals were fed a hepatopathogenic diet for 16 weeks and carbon tetrachloride (400 mg/kg, i.p.) and diethylnitrosamine (40 mg/kg, i.p.) were injected once a week. NAR was administered at 100 mg/kg p.o. The effects of NAR on the MASHHCC protocol were evaluated using biochemical, histological, in silico, and molecular biological approaches.</p><p><strong>Results: </strong>NAR significantly mitigated liver damage, as evidenced by the reduction in liver damage markers. It also reduced steatosis and inflammation, as determined by decreased lipid accumulation and sterol regulatory element-binding protein 1C, interleukins 1-beta and 18, and nuclear factor kappa B levels, and also increased peroxisome proliferator-activated receptor gamma levels. NAR inhibits the formation of NLRP3, including the recruitment of caspase-1 and gasdermin D proteins, and reduces the levels of transforming growth factor-beta, alpha-smooth muscle actin, and hepatic collagen 1, thereby diminishing extracellular matrix synthesis. Furthermore, gamma-glutamyl transpeptidase activity, glutathione S-transferase pi 1, and the proliferation marker KI67 were considerably reduced.</p><p><strong>Conclusions: </strong>Our findings show that NAR has the potential to inhibit early HCC induced in the context of MASH, thereby suggesting that NAR could be used for MASH treatment in humans.</p>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":" ","pages":"101897"},"PeriodicalIF":3.7,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143673183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum to \"Circ-LARP1B knockdown restrains the tumorigenicity and enhances radiosensitivity by regulating miR-578/IGF1R axis in hepatocellular carcinoma\" [Annals of Hepatology, Volume 27, (2022) 100678].","authors":"Shuangmei Zhu, Yong Chen, Hong Ye, Baoqiang Wang, Xiang Lan, Hanying Wang, Sijie Ding, Xiao He","doi":"10.1016/j.aohep.2025.101904","DOIUrl":"10.1016/j.aohep.2025.101904","url":null,"abstract":"","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":" ","pages":"101904"},"PeriodicalIF":3.7,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143673182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Updated recommendations for the management of metabolic dysfunction-associated steatotic liver disease (MASLD) by the Latin American working group.","authors":"Luis Antonio Diaz, Juan Pablo Arab, Francisco Idalsoaga, Javiera Perelli, Javier Vega, Melisa Dirchwolf, Javiera Carreño, Bárbara Samith, Cynthia Valério, Rodrigo Oliveira Moreira, Mónica Acevedo, Javier Brahm, Nelia Hernández, Adrian Gadano, Claudia P Oliveira, Marco Arrese, Graciela Castro-Narro, Mario G Pessoa","doi":"10.1016/j.aohep.2025.101903","DOIUrl":"10.1016/j.aohep.2025.101903","url":null,"abstract":"<p><p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is one of the leading causes of chronic liver disease globally. Based on the 2023 definition, MASLD is characterized by the presence of metabolic dysfunction and limited alcohol consumption (<140 grams/week for women, <210 grams/week for men). Given the significant burden of MASLD in Latin America, this guidance was developed by the Latin American Association for the Study of the Liver (ALEH) Working Group to address key aspects of its clinical assessment and therapeutic strategies. In Latin America, ultrasonography is recommended as the initial screening tool for hepatic steatosis due to its accessibility, while Fibrosis-4 (FIB-4) is preferred for fibrosis risk stratification, with further evaluation using more specific techniques (i.e., vibration-controlled transient elastography or Enhanced Liver Fibrosis [ELF] test). A Mediterranean diet is advised for all MASLD patients, with a target of 7-10% weight loss for those with excess weight. Complete alcohol abstinence is recommended for patients with significant fibrosis, and smoking cessation is encouraged regardless of fibrosis stage. Pharmacological options should be tailored based on the presence of steatohepatitis, liver fibrosis, excess weight, and diabetes, including resmetirom, incretin-based therapies, pioglitazone, and sodium-glucose cotransporter-2 inhibitors. Bariatric surgery may be considered for MASLD patients with obesity unresponsive to lifestyle and medical interventions. Hepatocellular carcinoma screening is advised for all cirrhotic patients, with consideration given to those with advanced fibrosis based on individual risk. Finally, routine cardiovascular risk assessment and proper diabetes prevention and management remain crucial for all patients with MASLD.</p>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":" ","pages":"101903"},"PeriodicalIF":3.7,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143633400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of hepatic encephalopathy in non-cirrhotic portal hypertension: A systematic review and meta-analysis.","authors":"Iris Campos Lucas, Edmundo Pessoa de Almeida Lopes Neto, Norma Arteiro Filgueira, Caroline Louise Diniz Pereira, Thais Campos Lucas, Ana Lúcia Coutinho Domingues","doi":"10.1016/j.aohep.2025.101902","DOIUrl":"10.1016/j.aohep.2025.101902","url":null,"abstract":"<p><strong>Introduction and objectives: </strong>The prevalence of hepatic encephalopathy (HE) in non-cirrhotic portal hypertension (NCPH) is not well established, despite evidence of its occurrence in both minimal (MHE) and overt forms (OHE). Accurate diagnosis and management of HE can reduce morbidity and improve patients' and their families' quality of life. This study aimed to systematically review the prevalence of HE in NCPH.</p><p><strong>Materials and methods: </strong>Systematic research in five databases (MEDLINE, LILACS, MEDRXIV, SCIELO and Scopus) was carried out from January to April 2024 to detect studies that address the prevalence of MHE and OHE in patients with NCPH, using the terms: \"Hepatic Encephalopathy\" or \"Psychometrics\" or \"Cognition Disorders\" or \"Cognition\" and \"Noncirrhotic Portal Hypertension\".</p><p><strong>Results: </strong>Twelve studies were included, including 575 patients. The prevalence of HE in patients with NCPH is 12 % (95 % CI: 6-24; I² 83 %, p<0.01), with high heterogeneity, with the pooled prevalence in studies evaluating MHE being 21 % (95 % CI: 11-38; I² 73 %, p<0.01) and the prevalence of OHE being 4 % (95 %CI: 1-15; I² 83 %, p<0.01). The prevalence of HE by etiology of NCPH is as follows: EHPVO is 25 % (95 %CI: 11-45; I² 0 %; p=1), PVT 2 % (95 %CI: 0-15; I² 0 %, p=1), in PSVD 8 % (95 %CI: 5-14; I² 87 %; p<0.01) and idiopathic NCPH 9 % (95 %CI: 5-14; I² 68 %, p<0.01), with the last two analyzes showing high heterogeneity.</p><p><strong>Conclusions: </strong>HE occurs in approximately 12 % of patients with NCPH, with MHE being more common than OHE. Etiology plays a significant role in HE prevalence.</p>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":" ","pages":"101902"},"PeriodicalIF":3.7,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143622993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}